GLP-1 Agonist Supply Chain Stabilizes, but Access Gaps Persist as Generic Timeline Remains Distant

Shortage Resolution and Its Consequences

The acute GLP-1 receptor agonist shortages that defined 2023 and 2024 have largely resolved, but the aftermath has created a complex landscape of supply improvements, access barriers, and regulatory consequences that continues to affect millions of patients. Both semaglutide and tirzepatide have been removed from the FDA's drug shortage list, yet demand continues to outpace supply for weight management indications, and the closure of the compounding pathway has left many patients without affordable alternatives.

The FDA removed tirzepatide from its national drug shortage list in December 2024 and pulled semaglutide in February 2025. Novo Nordisk and Eli Lilly have substantially increased their manufacturing capacity, investing billions in new production facilities to meet unprecedented demand. The improvements have resulted in better overall supply stability for brand-name products across their GLP-1 lines.

The Compounding Crackdown

With both drugs officially off the shortage list, the legal authorization that allowed compounding pharmacies to mass-produce GLP-1 agonists expired. Compounded semaglutide is no longer legal for routine dispensing. Grace periods ended in May 2025, and the FDA has been actively enforcing against pharmacies that continue mass compounding. This enforcement has eliminated what had been the primary source of affordable GLP-1 therapy for patients without insurance coverage or those facing high out-of-pocket costs.

The transition has not been smooth. Patient advocacy groups report that many individuals who were stable on compounded GLP-1 medications have been unable to transition to brand-name products due to cost barriers. Monthly list prices for brand-name semaglutide and tirzepatide remain above $1,000, though manufacturer savings programs and insurance negotiation have brought effective costs down for some patients.

First Generic GLP-1 Arrives

A significant milestone came in April 2025 when Meitheal Pharmaceuticals launched the first generic liraglutide injection, approved for type 2 diabetes. This marked the first generic GLP-1 receptor agonist on the U.S. market. Teva followed with its own generic liraglutide in mid-2025. While liraglutide is an older-generation GLP-1 with less dramatic weight loss efficacy than semaglutide or tirzepatide, the generic launches represent meaningful progress toward broader access.

Generic semaglutide, however, remains years away from market. Novo Nordisk's core semaglutide patents extend into the late 2020s, and the complexity of peptide manufacturing presents additional barriers to generic entry. Similarly, generic tirzepatide is not expected before 2030 at the earliest.

International Availability

Outside the United States, GLP-1 access varies dramatically. The European Medicines Agency has approved both semaglutide and tirzepatide for multiple indications, though national reimbursement decisions have been inconsistent. In the UK, the National Institute for Health and Care Excellence has recommended tirzepatide for type 2 diabetes, but weight management access remains restricted. Several countries in Asia and Latin America have approved these medications but face their own supply constraints.

Looking Ahead

The GLP-1 supply chain is entering a period of managed stability rather than crisis. Brand-name supply is improving, but affordability remains the central challenge. The arrival of generic liraglutide is a positive signal, though it addresses only a fraction of the demand. Patients and providers should expect continued supply tightness for weight management indications and should monitor developments around the SAFE Drugs Act, which could further reshape access pathways.

Novo Nordisk's amycretin entering Phase 3 trials in 2026 and multiple other next-generation peptide therapies in development offer long-term hope for a more competitive market, but near-term relief remains limited.